UNICREDIT BANK/PUT/MODERNA/110/0.1/19.06.24 | Market Closed - Borsa Italiana 01:34:59 18/05/2024 am IST | ||
| 0.082 EUR | -18.00% |
|
| Current month | -90.73% | ||
| 1 month | -93.73% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 17/24/17 | 0.0745 | -25.50% |
| 16/24/16 | 0.1 | -35.06% |
| 15/24/15 | 0.154 | -11.75% |
| 14/24/14 | 0.1745 | -12.97% |
| 13/24/13 | 0.2005 | -45.07% |
Real-time Borsa Italiana
Last update May 18, 2024 at 01:34 am IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | MODERNA, INC. |
| Issuer | 
UniCredit
|
| UD1W44 | |
| ISIN | DE000HD1W449 |
| Date issued | 15/01/2024 |
| Strike | 110 $ |
| Maturity | 19/06/2024 (31 Days) |
| Parity | 10 : 1 |
| Emission price | - € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.635 € |
|---|---|
| Lowest since issue | 0.066 € |
| Spread | 0.0085 € |
| Spread % | 9.94% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
132.9
USD
Average target price
138.5
USD
Spread / Average Target
+4.22%
- Stock Market
- Warrants
- UD1W44 Warrant